Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH3A1 | P30838 | 3/20 | 0.50 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6395129 | 0.83 | ALDH3A1 (0.67) | ALDH3A1HCAR3HTTTP53CYP19A1 | |
| SCHEMBL6819324 | 0.81 | ALDH3A1 (0.55) | ALDH3A1HCAR3HTTTP53CYP19A1 | |
| SCHEMBL13357839 | 0.80 | ALDH3A1 (0.46) | ALDH3A1HCAR3HTTTP53CYP19A1 | |
| SCHEMBL6929818 | 0.79 | ALDH3A1 (0.58) | ALDH3A1HCAR3HTTTP53CYP19A1 | |
| SCHEMBL5692166 | 0.73 | MAPT (0.62) | ALDH3A1MAPTALDH1A1TDP1TSHR | |
| SCHEMBL16583893 | 0.73 | MAPT (0.50) | ALDH3A1HCAR3HTTTP53CYP19A1 | |
| SCHEMBL13174835 | 0.72 | ALDH1A1 (0.45) | ALDH3A1HCAR3HTTTP53CYP19A1 | |
| SCHEMBL7567118 | 0.72 | ALDH3A1 (0.53) | ALDH3A1HCAR3HTTTP53CYP19A1 | |
| SCHEMBL14964149 | 0.71 | ALDH1A1 (0.39) | ALDH3A1HCAR3HTTTP53MAPT | |
| Ethane SCHEMBL3302283 | 0.71 | MAPT (0.60) | ALDH3A1MAPTALDH1A1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137704-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma, SA (CH) | 2013-05-30 | — | — | US | disclosed |
| US-20130131092-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma, SA (CH) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137704-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | ALDH3A1 3743/4885HCAR3 146/4885HTT 1943/4885 |
| US-20130131092-A1 | NOVEL AMIDO DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRM3 | ALDH3A1 3743/4885HCAR3 146/4885HTT 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.